

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MAZANET ROSEMARY (Last) (First) (Middle) C/O COLUMBIA CARE INC. 680 FIFTH AVENUE, 24TH FLOOR (Street) NEW YORK NY 10019 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Columbia Care Inc. [CCHW]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Scientific Officer
	3. Date of Earliest Transaction (Month/Day/Year) 04/29/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	04/29/2022		M		18,171	A	(1)	1,224,625	D	
Common Shares	04/29/2022		M		42,024	A	(1)	1,266,649	D	
Common Shares	04/29/2022		M		54,776	A	(1)	1,321,425	D	
Common Shares	04/29/2022		M		19,032	A	(1)	1,340,457	D	
Common Shares	04/29/2022		F		53,599	D	\$2.75 ⁽²⁾	1,286,858	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(1)	04/29/2022		M		18,171	(3)	(3)	(3)	Common Shares	18,171	\$0	54,513	D	
Restricted Stock Units	(1)	04/29/2022		M		42,024	(4)	(4)	(4)	Common Shares	42,024	\$0	0	D	
Restricted Stock Units	(1)	04/29/2022		M		54,776	(5)	(5)	(5)	Common Shares	54,776	\$0	109,551	D	
Restricted Stock Units	(1)	04/29/2022		M		19,032	(6)	(6)	(6)	Common Shares	19,032	\$0	19,032	D	

Explanation of Responses:

- Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- Converted from Canadian withholding price of C\$3.50 using an exchange rate of C\$1.2734 = US\$1.00.
- 72,684 RSUs were granted on March 23, 2021, and vest as follows: 1/4 annually beginning March 23, 2022. Settlement of vested RSUs will occur within 60 days of the applicable vesting date.
- 168,094 RSUs were granted on September 28, 2018, and vest as follows: 1/4 annually beginning March 31, 2019. Settlement of vested RSUs will occur within 60 days of the applicable vesting date.
- 219,102 RSUs were granted March 31, 2020, and vest as follows: 1/4 annually beginning March 31, 2021. Settlement of vested RSUs will occur within 60 days of the applicable vesting date.
- 76,127 RSUs were granted on September 28, 2019, and vest as follows: 1/4 annually beginning April 29, 2020. Settlement of vested RSUs will occur within 60 days of the applicable vesting date.

/s/ David Sirolly as attorney-in-fact for Rosemary Mazanet 05/02/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.